Breaking News

Rain Therapeutics Licenses MDM2 Inhibitor from Daiichi Sankyo

DS-3032 has been evaluated in clinical trials for solid tumors and hematologic malignancies.

By: Contract Pharma

Contract Pharma Staff

Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, has licensed worldwide rights to a clinical stage, small molecule, oral MDM2 inhibitor, DS-3032 (milademetan) from Daiichi Sankyo Company, Limited. Rain will re-designate the program as RAIN-32.   RAIN-32 is a potent and selective MDM2 inhibitor that has been evaluated in clinical trials for solid tumors and hematologic malignancies. The profile and dosing schedu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters